Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors

Abstract

Background

Several imaging modalities are used in the early work-up of patients with gastrointestinal stromal tumor (GIST) receiving tyrosine kinase inhibitor (TKI) treatment and there is a need to establish whether they provide similar or complimentary information.

Purpose

To compare 18F-fluorodeoxyglucose positron emission tomography (FDG PET), computed tomography (CT) and magnetic resonance imaging (MRI) as early predictors of three-month outcomes for patients with GIST receiving TKI treatment.

Material and Methods

Thirty-five patients with advanced GIST were prospectively included between February 2011 and June 2017. FDG PET, contrast-enhanced CT (CECT), and MRI were performed before and early after onset of TKI treatment (range 8–18 days). Early response was categorized according to mRECIST (CT), the Choi criteria (CECT), and PERCIST (FDG PET/CT). For MRI, volumetry from T2-weighted images and change in apparent diffusion coefficient (ADC) from diffusion-weighted imaging was used. The reference standard for early assessment was the three-month mRECIST evaluation based on CT. At three months, both stable disease (SD) and partial response (PR) were categorized as response. Clinical usefulness was defined as agreement between early and three-month assessment.

Results

At the three-month assessment, 91% (32/35) were responders, 37% (13/35) PR, 54% (19/35) SD, and 9% (3/35) had progressive disease (PD). Early assessment correctly predicted three-month response in 93% (27/29) for MRI, 80% (28/35) for PERCIST, 74% (26/35) for Choi, and 23% (8/35) for mRECIST. Six patients had non-FDG-avid tumors. For the FDG-avid tumors, PET/CT correctly predicted three-month response in 97% (28/29).

Conclusion

MRI was superior to CECT for early assessment of TKI-treatment response in GIST. If the tumor was FDG-avid, PET and MRI were equally good. Changes in functional parameters were superior to changes in longest tumor diameter (mRECIST).

Keywords

Gastrointestinal stromal tumor magnetic resonance imaging FDG PET/CT tyrosine kinase inhibitors clinical decision-making

Get full access to this article

View all access options for this article.

References

Joensuu

Roberts

Sarlomo-Rikala

, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052–1056.

Poveda

Garcia Del Muro

Lopez-Guerrero

, et al. GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treat Rev 2017; 55:107–119.

Antonescu

CR.

The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011; 223:251–261.

Joensuu

DeMatteo

RP.

The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 2012; 63:247–258.

Casali

Abecassis

Aro

, et al . Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv68–iv78.

Xia

Zhou

, et al. Prognostic value of tumor necrosis in gastrointestinal stromal tumor: A meta-analysis. Medicine (Baltimore) 2019; 98:e15338.

Dimitrakopoulou-Strauss

Ronellenfitsch

Cheng

, et al. Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging 2017; 5:183–197.

Van den Abbeele

Gatsonis

de Vries

, et al. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med 2012; 53:567–574.

Fangberget

Nilsen

Hole

, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 2011; 21:1188–1199.

10.

Galban

Hoff

Chenevert

, et al . Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed 2017; 30:10.1002/nbm.3458.

11.

Padhani

Liu

Koh

, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11:102–125.

12.

Revheim ME, Hole KH, Bruland OS, et al. DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour. Acta Oncol 2011;50:148–150.

13.

Revheim ME, Hole KH, Bruland OS, et al. Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Acta Oncol 2014;53:143–148.

14.

Benjamin

Choi

Macapinlac

, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760–1764.

15.

Zacharia

Saini

Halpern

, et al. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. AJR Am J Roentgenol 2006; 186:1067–1070.

16.

Wahl

Jacene

Kasamon

, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 Suppl 1:122S–150S.

17.

Kim

Soo

Bumwoo

, et al. Reproducibility of measurement of apparent diffusion coefficients of malignant hepatic tumors: Effect of DWI techniques and calculation methods. J Magn Reson Imaging 2012;36:1131–1138.

18.

Koh

Blackledge

Collins

, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009; 19:2728–2738.

19.

Miquel

Scott

Macdougall

, et al. In vitro and in vivo repeatability of abdominal diffusion-weighted MRI. Br J Radiol 2012;85:1507–1512.

20.

Eisenhauer

Therasse

Bogaerts

, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228–247.

21.

Blanke

Demetri

von Mehren

, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620–625.

22.

Choi

Role of imaging in response assessment and individualised treatment for sarcomas. Clin Oncol (R Coll Radiol) 2017; 29:481–488.

23.

Le Cesne

Van Glabbeke

Verweij

, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27:3969–3974.

24.

Corless

CL.

Medicine. Personalized cancer diagnostics. Science 2011; 334:1217–1218.

25.

Choi

Response evaluation of gastrointestinal stromal tumors. Oncologist 2008; 13 Suppl 2:4–7.

26.

Tang

, et al. MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study. BMC Cancer 2018; 18:811.

27.

Tang

Zhang

Sun

, et al. Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients. Radiology 2011; 258:729–738.

28.

Gong

Wong

Chu

, et al. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography. NMR Biomed 2013; 26:185–192.

29.

Schmidt

Dunet

Koehli

, et al. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT. Acta Radiol 2013; 54:837–842.

30.

Wong

Gong

Chu

, et al. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol 2012; 81:2122–2126.

31.

Schiavon

Ruggiero

Bekers

, et al. The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. Eur J Cancer 2014; 50:972–980.

32.

Schiavon

Ruggiero

Schoffski

, et al. Tumor volume as an alternative response measurement for imatinib treated GIST patients. PLoS One 2012; 7:e48372.

33.

Demetri

von

Antonescu

, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 Suppl 2:S1–41.

34.

Petralia

Padhani

AR.

Whole-body magnetic resonance imaging in oncology: uses and indications. Magn Reson Imaging Clin N Am 2018; 26:495–507.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.47 MB